Cipla cuts prices of 3 cancer drugs by up to 64 pct
REUTERS - Drugmaker Cipla (CIPL.NS) cut prices of three cancer drugs between 50 percent and 64 percent with immediate effect, after it announced similar price cuts for three drugs early this year.
Lung cancer drug Erlocip would cost 9,900 rupees for 30 tablets instead of 27,000 rupees earlier, while breast cancer treatment Docetax would be priced 1,650 rupees instead of 3,300 rupees, Cipla said in a statement on Thursday.
Cipla last month won a case against Roche Holding (ROG.VX), which accused the Indian company of infringing patent on cancer drug Tarceva, which Cipla sells under the brand name Erlocip.
Capegard, another drug to treat metastatic colorectal and colon caner, would be priced 600 rupees for 10 tablets instead of 1,200 rupees, it said. (Reporting by Kaustubh Kulkarni and Manoj Dharra in Mumbai; Editing by Subhranshu Sahu)
- Tweet this
- Share this
- Digg this
- Hong Kong protests approach potential National Day flashpoint
- OPEC oil output hits highest since 2012 on Libya, Saudi-Reuters Survey
- Obama, Modi discuss trade, climate, Islamic State at White House
- UPDATE 3-Drug, medical device companies paid billions to U.S. physicians, hospitals in 2013 -data
- UPDATE 2-U.S. charges four with stealing $100 mln in software, data
U.S. President Barack Obama and Indian Prime Minister Narendra Modi worked to deepen improving ties between their countries on Tuesday, but emerged from their second meeting in two days with little in the way of major agreements. Story | Full Coverage
China final HSBC PMI steady in September on stronger global demand but risks remain Full Article